|
US7220717B2
(en)
|
1997-08-14 |
2007-05-22 |
Yeda Research And Development Company Ltd. |
Interleukin-18 binding proteins, their preparation and use
|
|
US7704944B2
(en)
|
1997-08-14 |
2010-04-27 |
Yeda Research And Development Company Ltd. |
Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
|
|
IL121860A0
(en)
|
1997-08-14 |
1998-02-22 |
Yeda Res & Dev |
Interleukin-18 binding proteins their preparation and use
|
|
FR2781483A1
(fr)
*
|
1998-07-21 |
2000-01-28 |
Hoechst Marion Roussel Inc |
Derives de thioazepinone, procede de preparation et intermediaires de ce procede, application a titre de medicament et compositions pharmaceutiques les renfermant
|
|
US7015212B1
(en)
|
1999-05-12 |
2006-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Thiazepine inhibitors of HIV-1 integrase
|
|
CN1326562C
(zh)
*
|
2001-01-29 |
2007-07-18 |
应用研究系统Ars股份公司 |
Il－18抑制剂制造治疗和/或预防心脏病的药物的应用
|
|
WO2002066063A1
(en)
*
|
2001-02-23 |
2002-08-29 |
Nippon Organon K.K. |
Remedies for metabolic bone diseases
|
|
US7001899B2
(en)
*
|
2002-06-10 |
2006-02-21 |
The Procter & Gamble Company |
Interleukin converting enzyme inhibitors
|
|
ES2422193T3
(es)
|
2002-06-28 |
2013-09-09 |
Life Technologies Corp |
Métodos para restaurar el repertorio inmune en pacientes con defectos inmunológicos relacionados con la autoinmunidad y trasplante de órganos o de células madre hematopoyéticas
|
|
EP2025345A1
(en)
*
|
2002-12-30 |
2009-02-18 |
Biogen Idec MA Inc. |
KIM-1 antagonists and use to modulate immune system
|
|
WO2005115362A1
(en)
*
|
2004-05-15 |
2005-12-08 |
Vertex Pharmaceuticals Incorporated |
Treating seizures using ice inhibitors
|
|
EP1831225A2
(en)
*
|
2004-11-19 |
2007-09-12 |
The Regents of the University of California |
Anti-inflammatory pyrazolopyrimidines
|
|
KR101213894B1
(ko)
|
2005-03-02 |
2012-12-20 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Ｔｈ2 매개성 병태를 치료하기 위한 ｋｉｍ-1 항체
|
|
WO2007114926A2
(en)
|
2006-04-04 |
2007-10-11 |
The Regents Of The University Of California |
Kinase antagonists
|
|
GB2467670B
(en)
*
|
2007-10-04 |
2012-08-01 |
Intellikine Inc |
Chemical entities and therapeutic uses thereof
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
MX2010007419A
(es)
*
|
2008-01-04 |
2010-11-12 |
Intellikine Inc |
Ciertas entidades quimicas, composiciones y metodos.
|
|
EP2252293B1
(en)
*
|
2008-03-14 |
2018-06-27 |
Intellikine, LLC |
Kinase inhibitors and methods of use
|
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
|
BRPI0915231A2
(pt)
*
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
|
US20110224223A1
(en)
*
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
|
CA2738429C
(en)
|
2008-09-26 |
2016-10-25 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
|
EP2358720B1
(en)
|
2008-10-16 |
2016-03-02 |
The Regents of The University of California |
Fused ring heteroaryl kinase inhibitors
|
|
BRPI0914035A2
(pt)
*
|
2008-10-17 |
2015-11-03 |
Koninkl Philips Electronics Nv |
ventilador e método para ventilar um paciente usando um ventilador
|
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン， エルエルシー |
複素環式化合物およびその使用
|
|
WO2011047384A2
(en)
|
2009-10-16 |
2011-04-21 |
The Regents Of The University Of California |
Methods of inhibiting ire1
|
|
CA2799579A1
(en)
|
2010-05-21 |
2011-11-24 |
Intellikine, Inc. |
Chemical compounds, compositions and methods for kinase modulation
|
|
SG189985A1
(en)
|
2010-10-26 |
2013-06-28 |
Presidio Pharmaceuticals Inc |
Inhibitors of hepatitis c virus
|
|
JP2013545749A
(ja)
|
2010-11-10 |
2013-12-26 |
インフィニティー ファーマシューティカルズ， インコーポレイテッド |
複素環化合物及びその使用
|
|
ES2637113T3
(es)
|
2011-01-10 |
2017-10-10 |
Infinity Pharmaceuticals, Inc. |
Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
|
|
US9295673B2
(en)
|
2011-02-23 |
2016-03-29 |
Intellikine Llc |
Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
|
|
HK1198443A1
(en)
|
2011-07-19 |
2015-04-24 |
无限药品股份有限公司 |
Heterocyclic compounds and uses thereof
|
|
AR088218A1
(es)
|
2011-07-19 |
2014-05-21 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos utiles como inhibidores de pi3k
|
|
US9956260B1
(en)
|
2011-07-22 |
2018-05-01 |
The J. David Gladstone Institutes |
Treatment of HIV-1 infection and AIDS
|
|
MX2014002542A
(es)
|
2011-08-29 |
2014-07-09 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos.
|
|
CA2846496C
(en)
|
2011-09-02 |
2020-07-14 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
JP2015532287A
(ja)
|
2012-09-26 |
2015-11-09 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
Ｉｒｅ１の調節
|
|
AU2013337717B2
(en)
|
2012-11-01 |
2018-10-25 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using PI3 kinase isoform modulators
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
PT3052485T
(pt)
|
2013-10-04 |
2021-10-22 |
Infinity Pharmaceuticals Inc |
Compostos heterocíclicos e suas utilizações
|
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CN103804367B
(zh)
*
|
2014-02-28 |
2016-09-14 |
天津药物研究院 |
苯并氮杂卓衍生物、其制备方法和用途
|
|
MX382033B
(es)
|
2014-03-19 |
2025-03-13 |
Infinity Pharmaceuticals Inc |
Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3317269B1
(en)
|
2015-07-02 |
2022-09-21 |
F. Hoffmann-La Roche AG |
Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases
|
|
WO2017048702A1
(en)
|
2015-09-14 |
2017-03-23 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
|
|
IL287136B2
(en)
|
2016-02-05 |
2023-09-01 |
Denali Therapeutics Inc |
Receptor inhibitors - interacting with protein kinase 1
|
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
SG11201811237WA
(en)
|
2016-06-24 |
2019-01-30 |
Infinity Pharmaceuticals Inc |
Combination therapies
|
|
WO2018073193A1
(en)
|
2016-10-17 |
2018-04-26 |
F. Hoffmann-La Roche Ag |
Bicyclic pyridone lactams and methods of use thereof
|
|
JP7208137B2
(ja)
|
2016-12-09 |
2023-01-18 |
デナリ セラピューティクス インコーポレイテッド |
化合物、組成物および方法
|
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
|
WO2019204537A1
(en)
|
2018-04-20 |
2019-10-24 |
Genentech, Inc. |
N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
|
|
TW202334164A
(zh)
|
2022-01-12 |
2023-09-01 |
美商戴納立製藥公司 |
（Ｓ）－５－苄基－Ｎ－（５－甲基－４－側氧基－２，３，４，５－四氫吡啶並［３，２－ｂ］［１，４］氧氮呯－３－基）－４Ｈ－１，２，４－三唑－３－甲醯胺的晶型
|
|
WO2026082873A1
(en)
|
2024-10-17 |
2026-04-23 |
Institut National de la Santé et de la Recherche Médicale |
Use of caspase-1 inhibitors for treating ineffective erythropoiesis in patients suffering from sickle cell disease
|